A Phase I/II Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9?Engineered T Cells CTX110 in Subjects with Relapsed or Refractory B-Cell Malignancies

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT04035434

Study #:
STUDY00143893

Start Date:
Aug 15, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04035434

View Complete Trial Details & Eligibility at ClinicalTrials.gov